DRAK2 Antibody
| Code | Size | Price |
|---|
| PSI-2149-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-2149-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
DRAK2 Antibody: DRAK2, DRAK2, DAP kinase-related apoptosis-inducing protein kinase 2
Application Note:
DRAK2 antibody can be used for detection of DRAK2 by Western blot 0.5 μg/mL. An approximately 45 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 10 μg/mL.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Background:
DRAK2 Antibody: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
Background References:
- Sanjo H, Kawai T, Akira S. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J Biol Chem 1998;273:29066-71 (RD1299)
Buffer:
DRAK2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (93%), Rat: (93%)
Immunogen:
DRAK2 antibody was raised against a 15 amino acid peptide near the carboxy terminus of human DRAK2.
The immunogen is located within the last 50 amino acids of DRAK2.
The immunogen is located within the last 50 amino acids of DRAK2.
NCBI Gene ID #:
9262
NCBI Official Name:
serine/threonine kinase 17b
NCBI Official Symbol:
STK17B
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AB011421
Protein GI Number:
3834355
Purification:
DRAK2 Antibody is Ion exchange chromatography purified.
Research Area:
Apoptosis,Autophagy
SPECIFICITY:
It has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable.
Swissprot #:
O94768
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | DRAK2 Peptide | PSI-2149P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|